NCT05292638View on ClinicalTrials.gov

Safety and Efficacy of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 15, 2022

Primary Completion Date

June 10, 2022

Study Completion Date

June 10, 2022

Conditions
Glabellar Lines
Interventions
DRUG

CKDB-501A

Intramuscular injection CKDB-501A

DRUG

Botox®

Intramuscular injection Botox®

Trial Locations (1)

Unknown

Chung-Ang University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

CKD Bio Corporation

INDUSTRY

NCT05292638 - Safety and Efficacy of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines | Biotech Hunter | Biotech Hunter